文献速递淋巴瘤

滤泡性淋巴瘤POD24患者的治疗与生存结局:系统综述与荟萃分析

Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2026-01-01

该系统综述与荟萃分析纳入21项试验共1242例POD24滤泡性淋巴瘤患者,评估ORR、CR、缓解持续时间及PFS。汇总分析显示抗CD19 CAR-T细胞治疗CR率最高,双特异性抗体、抗CD19 ADC/单抗及来那度胺联合方案亦显示良好疗效,来那度胺联合奥妥珠单抗优于R2。

要点

  • 抗CD19 CAR-T细胞治疗在POD24患者中取得最高CR率
  • 双特异性抗体汇总ORR 81.6%、CR 65.7%,异质性低
  • 来那度胺联合奥妥珠单抗疗效优于来那度胺联合利妥昔单抗

核心结论

  • 抗CD19 CAR-T细胞治疗在POD24滤泡性淋巴瘤中达到最高完全缓解率。
  • 双特异性抗体、抗CD19 ADC/单抗及来那度胺联合奥妥珠单抗或利妥昔单抗亦显示优异疗效。
  • 来那度胺联合奥妥珠单抗疗效优于来那度胺联合利妥昔单抗。

研究设计与样本

  • 系统综述与汇总分析,纳入21项试验共1242例POD24患者。
  • 评估指标包括总缓解率、完全缓解、缓解持续时间及无进展生存期。
  • 部分试验比较了相同方案下POD24与非POD24人群的汇总缓解率。
  • 4项试验评估了CAR-T细胞治疗在POD24患者中的应用。

主要发现

  • 汇总分析ORR为91.2%(95%CI 83.7-98.7),异质性显著(P=.0414;I2=68.61%)。
  • 汇总分析CR为75.7%(95%CI 55.1-96.4),异质性显著(P<.0001;I2=93.99%)。
  • 双特异性抗体汇总ORR为81.6%(95%CI 75.9-87.3),无异质性(P=.6958;I2=0%)。
  • 双特异性抗体汇总CR为65.7%(95%CI 57.1-74.3),中度异质性(P=.2148;I2=34.99%)。
  • loncastuximab联合利妥昔单抗的ORR和CR分别为100%和79.3%;tafasitamab联合R2分别为87.5%和43.2%。

关键数值与推荐

  • 抗CD19 CAR-T细胞治疗在POD24患者中CR率最高。
  • 双特异性抗体汇总ORR 81.6%(95%CI 75.9-87.3),CR 65.7%(95%CI 57.1-74.3)。
  • loncastuximab联合利妥昔单抗ORR 100%、CR 79.3%。
  • tafasitamab联合R2(来那度胺+利妥昔单抗)ORR 87.5%、CR 43.2%。
  • 来那度胺联合奥妥珠单抗疗效优于R2。

临床怎么用

  • POD24滤泡性淋巴瘤患者可优先考虑抗CD19 CAR-T细胞治疗以追求最高完全缓解。
  • 双特异性抗体、抗CD19 ADC/单抗及来那度胺联合奥妥珠单抗或利妥昔单抗可作为有效治疗选择。
  • 来那度胺联合奥妥珠单抗较R2显示更优疗效,可作为方案选择参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma with progression of disease within 24 months (POD24) is associated with poor prognosis and represents clinical challenges. Therefore, we performed a systematic review and pooled analysis of patients with POD24. Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same treatment regimen. Four trials evaluated chimeric antigen receptor (CAR) T-cell therapy in patients with POD24. Pooled analysis showed an ORR of 91.2% (95% confidence interval [CI], 83.7-98.7) with significant heterogeneity (P = .0414; I2 = 68.61%) and a CR of 75.7% (95% CI, 55.1-96.4) with significant heterogeneity (P< .0001; I2 = 93.99%). The specific response rates for different bispecific antibodies in POD24 were pooled analysis, the ORR was 81.6% (95% CI, 75.9-87.3) with no heterogeneity (P = .6958; I2 = 0%), and the CR was 65.7% (95% CI, 57.1-74.3) with moderate heterogeneity (P = .2148; I2 = 34.99%). For anti-CD19 antibody-drug conjugates (ADCs)/monoclonal antibodies (mAbs), the ORR and CR rate for loncastuximab plus rituximab and tafasitamab plus R2 (lenalidomide + rituximab) were 100% and 79.3%, and 87.5% and 43.2%, respectively. Phosphatidylinositol 3-kinase inhibitors and anti-CD20 mAb-containing regimens were also analyzed in pooled analyses. Our results demonstrated that anti-CD19 CAR T-cell therapy achieved the highest CR rate. Additionally, bispecific antibodies, anti-CD19 ADCs/mAbs, and the combination of lenalidomide with obinutuzumab or rituximab also exhibited excellent efficacy. Notably, lenalidomide plus obinutuzumab showed superior efficacy compared with R2.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shen J, Zhang J, Zhu Z, et al. Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis. Blood Adv. 2026. PMID: 41587420. doi:10.1182/bloodadvances.2025018474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。